This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, W. Articles by Robbins, R. J. Search for Related Content PubMed PubMed Citation Articles by Wang, W. Articles by Robbins, R. J.

Prognostic Value of [¹⁸F]Fluorodeoxyglucose Positron Emission Tomographic Scanning in Patients with Thyroid Cancer¹

Nuclear Medicine and Endocrinology Services, Departments of Radiology (W.W., S.M.L., H.Y., H.M.), Medicine (R.R.), Medical Physics (K.K., G.S.), Epidemiology and Biostatistics (M.F.), and Pathology (S.T., J.R.), The Laurent and Alberta Gerschel PET Center, Memorial Sloan Kettering Cancer Center, New York, New York 10021

Address all correspondence and requests for reprints to: Richard J. Robbins, M.D., Endocrinology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021.

Poorly differentiated thyroid cancer lesions often lose the ability to concentrate radioactive [¹³¹I]iodine (RAI) and exhibit increased metabolic activity, as evidenced by enhanced glucose uptake. We incorporated [¹⁸F]fluorodeoxyglucose (FDG) positron emission tomography (PET) scanning into the routine follow-up of a cohort of thyroid cancer patients undergoing annual evaluations. One hundred and twenty-five patients who had previous thyroidectomies were included. They had diagnostic RAI whole body scans, serum thyroglobulin measurements, and additional imaging studies as clinically indicated. During 41 months of follow-up, 14 patients died. Univariate analysis demonstrated that survival was reduced in those with age over 45 yr, distant metastases, PET positivity, high rates of FDG uptake, and high volume of the FDG-avid disease (>125 mL). Survival did not correlate with gender, RAI uptake, initial histology, or grade. Multivariate analysis demonstrated that the single strongest predictor of survival was the volume of FDG-avid disease. The 3-yr survival probability of patients with FDG volumes of 125 mL or less was 0.96 (95% confidence interval, 0.91, 1.0) compared with 0.18 (95% confidence interval, 0.04, 0.85) in patients with FDG volume greater than 125 mL. Only 1 death (of leukemia) occurred in the PET-negative group (n = 66). Of the 10 patients with distant metastases and negative PET scans, all were alive and well. Patients over 45 yr with distant metastases that concentrate FDG are at the highest risk. Once distant metastases are discovered in patients with differentiated thyroid carcinoma, FDG-PET can identify high and low risk subsets. Subjects with a FDG volume greater than 125 mL have significantly reduced short term survival.

This article has been cited by other articles:

				C. Romei, R. Ciampi, P. Faviana, L. Agate, E. Molinaro, V. Bottici, F. Basolo, P. Miccoli, F. Pacini, A. Pinchera, et al. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer Endocr. Relat. Cancer, June 1, 2008; 15(2): 511 - 520. [Abstract] [Full Text] [PDF]

				A. S Al-Zahrani, M.-E. M Abouzied, S. A. Salam, G. Mohamed, A. Rifai, A. Al Sugair, and T. Amin The role of F-18-fluorodeoxyglucose positron emission tomography in the postoperative evaluation of differentiated thyroid cancer Eur. J. Endocrinol., May 1, 2008; 158(5): 683 - 689. [Abstract] [Full Text] [PDF]

				R. T. Kloos Approach to the Patient with a Positive Serum Thyroglobulin and a Negative Radioiodine Scan after Initial Therapy for Differentiated Thyroid Cancer J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1519 - 1525. [Abstract] [Full Text] [PDF]

				M M Muresan, P Olivier, J Leclere, F Sirveaux, L Brunaud, M Klein, R Zarnegar, and G Weryha Bone metastases from differentiated thyroid carcinoma Endocr. Relat. Cancer, March 1, 2008; 15(1): 37 - 49. [Abstract] [Full Text] [PDF]

				D. A. Mankoff, J. F. Eary, J. M. Link, M. Muzi, J. G. Rajendran, A. M. Spence, and K. A. Krohn Tumor-Specific Positron Emission Tomography Imaging in Patients: [18F] Fluorodeoxyglucose and Beyond Clin. Cancer Res., June 15, 2007; 13(12): 3460 - 3469. [Abstract] [Full Text] [PDF]

				O. Israel and A. Kuten Early Detection of Cancer Recurrence: 18F-FDG PET/CT Can Make a Difference in Diagnosis and Patient Care J. Nucl. Med., January 1, 2007; 48(1_suppl): 28S - 35S. [Abstract] [Full Text] [PDF]

				D. A. Pryma, H. Schoder, M. Gonen, R. J. Robbins, S. M. Larson, and H. W.D. Yeung Diagnostic Accuracy and Prognostic Value of 18F-FDG PET in Hurthle Cell Thyroid Cancer Patients J. Nucl. Med., August 1, 2006; 47(8): 1260 - 1266. [Abstract] [Full Text] [PDF]

				H. Palmedo, J. Bucerius, A. Joe, H. Strunk, N. Hortling, S. Meyka, R. Roedel, M. Wolff, E. Wardelmann, H.-J. Biersack, et al. Integrated PET/CT in Differentiated Thyroid Cancer: Diagnostic Accuracy and Impact on Patient Management J. Nucl. Med., April 1, 2006; 47(4): 616 - 624. [Abstract] [Full Text] [PDF]

				S. Leboulleux, C. Dromain, G. Bonniaud, A. Auperin, B. Caillou, J. Lumbroso, R. Sigal, E. Baudin, and M. Schlumberger Diagnostic and Prognostic Value of 18-Fluorodeoxyglucose Positron Emission Tomography in Adrenocortical Carcinoma: A Prospective Comparison with Computed Tomography J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 920 - 925. [Abstract] [Full Text] [PDF]

				G. N. Mann, J. M. Link, P. Pham, C. A. Pickett, D. R. Byrd, P. E. Kinahan, K. A. Krohn, and D. A. Mankoff [11C]Metahydroxyephedrine and [18F]Fluorodeoxyglucose Positron Emission Tomography Improve Clinical Decision Making in Suspected Pheochromocytoma Ann. Surg. Oncol., February 1, 2006; 13(2): 187 - 197. [Abstract] [Full Text] [PDF]

				R. J. Robbins, Q. Wan, R. K. Grewal, R. Reibke, M. Gonen, H. W. Strauss, R. M. Tuttle, W. Drucker, and S. M. Larson Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-D-Glucose-Positron Emission Tomography Scanning J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 498 - 505. [Abstract] [Full Text] [PDF]

				G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development Clin. Cancer Res., April 15, 2005; 11(8): 2785 - 2808. [Abstract] [Full Text] [PDF]

				L. Hooft, A. A. M. van der Veldt, P. J. van Diest, O. S. Hoekstra, J. Berkhof, G. J. J. Teule, and C. F. M. Molthoff [18F]Fluorodeoxyglucose Uptake in Recurrent Thyroid Cancer Is Related to Hexokinase I Expression in the Primary Tumor J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 328 - 334. [Abstract] [Full Text] [PDF]

				K. Pacak, G. Eisenhofer, and D. S. Goldstein Functional Imaging of Endocrine Tumors: Role of Positron Emission Tomography Endocr. Rev., August 1, 2004; 25(4): 568 - 580. [Abstract] [Full Text] [PDF]

				K. Pacak, I. Ilias, C. C. Chen, J. A. Carrasquillo, M. Whatley, and L. K. Nieman The Role of [18F]Fluorodeoxyglucose Positron Emission Tomography and [111In]-Diethylenetriaminepentaacetate-D-Phe-Pentetreotide Scintigraphy in the Localization of Ectopic Adrenocorticotropin-Secreting Tumors Causing Cushing's Syndrome J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2214 - 2221. [Abstract] [Full Text] [PDF]

				N Khan, N Oriuchi, T Higuchi, H Zhang, and K Endo PET in the follow-up of differentiated thyroid cancer Br. J. Radiol., October 1, 2003; 76(910): 690 - 695. [Abstract] [Full Text] [PDF]

				A. Van den Bruel, A. Maes, T. De Potter, L. Mortelmans, M. Drijkoningen, B. Van Damme, P. Delaere, and R. Bouillon Clinical Relevance of Thyroid Fluorodeoxyglucose-Whole Body Positron Emission Tomography Incidentaloma J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1517 - 1520. [Abstract] [Full Text] [PDF]

				L. Hooft, O. S. Hoekstra, W. Deville, P. Lips, G. J. J. Teule, M. Boers, and M. W. van Tulder Diagnostic Accuracy of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Follow-Up of Papillary or Follicular Thyroid Cancer J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3779 - 3786. [Abstract] [Full Text] [PDF]

				H. A. Macapinlac Clinical Usefulness of FDG PET in Differentiated Thyroid Cancer J. Nucl. Med., January 1, 2001; 42(1): 77 - 78. [Full Text] [PDF]